Recent studies [79,80] using lupus-prone mice show opposite effects via PAR2 to induce kidney disease; A PAR2 agonist has been shown to suppress IRF5 [28] (an important IFN regulatory factor implicated in lupus) in macrophages. This evidence concerns the gene IRF5 and systemic lupus erythematosus.